John Blankenhorn

John Blankenhorn

InvestorPlace Contributor

Expertise: Biochemistry, biotechnology and pharmaceutical research

John Blankenhorn has been a researcher since 2016 and has years of experience and publications on the topics of biochemistry, biotechnology, and pharmaceutical research. His main interests are the application of biology and biotechnology to our daily lives, as well as the use of Machine Learning and AI to speed up research and development in the life sciences. He currently works at Emory University studying the structural basis of Alzheimer’s Disease.

Recent Articles

3 Hydrogen Stocks to Make You the Millionaire Next Door

By John Blankenhorn, InvestorPlace Contributor

Hydrogen is booming as both a green source of energy and an industrial feedstock for our most important chemicals. Don't miss out on the gains available.

The 3 Quantum Computing Stocks You Need to Own Now for Maximum Returns

By John Blankenhorn, InvestorPlace Contributor

Finding the best quantum computing stocks to buy is critical because this is clearly the next big industry.

Hero or Zero? 3 High-Risk Biotech Stocks to Make You Rich … or Broke.

By John Blankenhorn, InvestorPlace Contributor

These biotech companies are swinging for the fences. They may hit homers, they may strike out. But you'll definitely want to watch them.

3 Personalized Medicine Stocks to Buy for Long-Time Returns

By John Blankenhorn, InvestorPlace Contributor

Personalized medicine is the future of medicine. Here are three personalized medicine stocks to invest in so you don't miss out.

3 DNA Stocks to Buy for the Synthetic Biology Revolution

By John Blankenhorn, InvestorPlace Contributor

Synthetic biology is a growing industry. The big winners will be DNA stocks that are able to sell to everyone, not just a small niche.

Load More